0000950170-25-113026
SEC filingRevenue declined 11.7% YoY but gross margin expanded 840 bps to 40.1% driven by favorable mix shift away from Mainland China.
For Q2 2025, Ambiq Micro reported net sales of $17.9 million, a decline of 11.7% from $20.3 million in Q2 2024. The decrease was primarily driven by the strategic prioritization of non-Mainland China opportunities, with Mainland China sales plummeting from 42% of total revenue to just 12%. Despite the top-line decline, gross profit increased 11.8% to $7.2 million, while gross margin expanded 840 basis points to 40.1%. This margin improvement was attributed to a more favorable product and customer mix as the company shifted focus to higher-margin markets outside China. Operating expenses decreased 8.5% overall, with R&D down 5.2% and SG&A down 11.4% (the latter benefiting from the absence of a warrant issuance in the prior year). Net loss improved to $8.5 million from $10.6 million, a 19.8% reduction.
For the six-month period, trends were similar: revenue declined 5.2% to $33.6 million, but gross profit rose 23.0% to $15.6 million, driving gross margin up 1,060 bps to 46.3%. Net loss improved to $16.8 million from $20.0 million.
Ambiq does not report formal product segments but provides geographic and customer concentration details. The company is actively shifting its geographical concentration away from Mainland China, which historically accounted for 66% of sales in 2023 and 50% in 2024, down to 12% in Q2 2025. Non-Mainland China revenue grew 34.7% YoY to $15.9 million in Q2 2025, contributing to the gross margin expansion. Customer concentration remains high, with top ten end customers representing 98% of net sales in H1 2025, and the largest customer at 38%. The company is investing in product development to support new markets in medical/healthcare, industrial edge, and smart home and buildings.
No specific forward guidance was provided in the MD&A. However, management expects the geographic shift away from Mainland China to continue, which should further improve margins. The company completed an IPO in July 2025, raising net proceeds of $97.2 million, bolstering its cash position to support R&D and expansion. Ambiq anticipates incurring losses until it can generate significant sales from products in development. The MD&A does not discuss specific revenue or margin targets, but the strategic focus on higher-margin non-China markets and new product introductions suggests a continued emphasis on margin improvement over top-line growth in the near term.
As of June 30, 2025, Ambiq Micro held $47.5 million in cash and cash equivalents, a decrease from $61.0 million at year-end 2024, driven by operating cash outflows of $10.5 million in the first half. Total assets stood at $89.2 million, with inventories of $15.8 million (up from $15.0 million) and accounts receivable of $7.8 million. The company has total lease liabilities of $0.9 million and negative stockholders' deficit of -$307.3 million, primarily due to accumulated deficit of -$337.0 million.
The company has manufacturing purchase commitments of $7.7 million as of June 30, 2025, under purchase orders with its third-party foundry and contract manufacturer. These commitments are cancellable upon agreement but represent near-term obligations. No other material contractual obligations were disclosed.
No share buybacks or dividends were declared during the period. Capital expenditures totaled $3.1 million for the six months ended June 30, 2025, comprising $2.7 million for intangible assets and $0.5 million for property and equipment, representing 9.4% of net sales. The company did not issue or repay debt; the post-period IPO (July 2025) raised net proceeds of $97.2 million, which will improve liquidity.
Ambiq Micro operates as a single reportable segment. Revenue by shipment destination for the six months ended June 30, 2025: China $14.3M, Taiwan $12.8M, Singapore $5.7M, and Rest of World $0.8M. End customer concentration is high: three customers represented 83% of Q2 2025 net sales. The company relies on a sole wafer supplier and limited third-party manufacturers.
CFO of -$10.5M was driven by a net loss of $16.8M, partially offset by non-cash charges (depreciation $3.8M, stock comp $1.6M, gain on nonmonetary assets $1.6M) and working capital inflows (accounts receivable down $2.7M, accounts payable up $0.9M). The CFO deficit worsened $5.4M YoY due to a $3.2M higher net loss and an inventory build of $0.8M versus a $11.0M drawdown in prior year.
Capex of $0.5M (property, equipment, software) plus $2.7M in intangible asset purchases resulted in total investing outflow of $3.1M. No free cash flow or capital returns are disclosed.
Financing activities were minimal ($0.2M from option exercises) compared to $51.8M in H1 2024 from preferred stock issuance. The company ended with $47.5M cash, down from $61.0M at beginning of period.
Anomalies: Large non-cash gain on nonmonetary assets ($1.6M), significant intangible asset purchases ($2.7M) financed partly through payables ($8.3M), and a sharp drop in financing proceeds highlight reliance on existing cash and potential need for future funding.